Terra L. Lasho

ORCID: 0000-0002-0315-5230 · 1 paper in corpus

article 2007

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

·doi:10.1182/blood.v110.11.3555.3555

Abstract BACKGROUND: The potential risks of tumor growth promotion and thromboembolism associated with erythropoietin (Epo) therapy warrant cautious use of erythropoiesis stimulating agents (ESA). Recent data suggest a surprising and signif…